Orthofix Trims 2026 View as U.S. Spine Woes Persist

Orthofix Medical (NASDAQ:OFIX) lowered its full-year outlook to $825 million to $830 million in pro forma net sales after third-quarter revenue of $207.9 million, up 2.3 percent year over year, fell short of management's expectations. Softer U.S. spine procedure volumes and supplier delays, the company said, constrained its ability to support demand. The medical device maker also guided to full-year adjusted EBITDA (a profitability measure excluding interest, taxes, depreciation and amortization) of $86 million to $88 million.

The diagnosis was blunt. President and CEO Massimo Calafiore said Orthofix is accelerating changes to its U.S. spine distribution network, concentrating resources on stronger partners and products while simplifying the portfolio and aligning costs. Those changes, together with supplier delays, are expected to pressure sales in the near term.

What went wrong in spine?

Global spinal implants, biologics and enabling technologies generated $107.4 million in quarterly sales, down approximately 1 percent from a year earlier. Global spine fixation sales rose 1 percent on a constant-currency basis, while U.S. spine fixation declined 5 percent. That divergence is the story in one line.

CFO Julie Andrews said supplier delays and instrument-set constraints limited Orthofix's ability to consistently support demand among its top 30 distributors. Their growth slowed to the mid-single digits but remained above the market, she said.

Calafiore told analysts that procedure volumes were weaker among some top customers, but said he did not believe the company was losing market share. He attributed the supply issues to delays in instrument manufacturing and certain interbody product lines, and said the company is working with suppliers to resolve them by the end of the fourth quarter.

The remedy is selective retreat. Orthofix is exiting lower-performing distributor relationships and redeploying instrument sets to core partners, which Calafiore said account for approximately 80 percent of U.S. spinal implant revenue. He said the company expects progress in stages, beginning with better inventory and instrument availability before stronger growth from core products and partners.

The product pipeline offers some cheer. Orthofix continues to expect a full market launch of its VIRATA spinal implant system for open procedures later in the fourth quarter. The company also received two 510(k) clearances (the U.S. Food and Drug Administration's standard premarket notification pathway) during the quarter for software enhancements to its 7D navigation system.

Where is the growth coming from?

The non-spine businesses did the lifting. Therapeutic Solutions posted $64 million in sales, up 4 percent year over year, with Calafiore citing 4 percent volume growth above the market alongside strong margins and cash generation.

Global Limb Reconstruction sales increased 9 percent on a constant-currency basis to $36.4 million, supported by international demand. Andrews said the FITBONE and TRUELOK Elevate platforms each grew more than 20 percent, although U.S. Limb Reconstruction growth was essentially flat. In September, Orthofix submitted a 510(k) premarket notification for an automated version of TRUELOK Elevate. Calafiore said the company is also pursuing potential additional indications for its technologies, including diabetic foot ulcer.

U.S. biologics sales were roughly flat sequentially despite typical seasonal softness, which management viewed as a sign of stabilization. Calafiore said the business returned to positive year-over-year growth in October, though Andrews cautioned that sustained improvement is still needed.

How does the guidance break down?

Adjusted EBITDA for the third quarter rose to $26 million, or 12.5 percent of pro forma net sales, from $24.6 million, or 12.1 percent, a year earlier. Andrews attributed the improvement primarily to cost discipline and resource alignment, partly offset by lower spine revenue, unfavorable geographic mix and reduced operating leverage.

The revised outlook reflects several moving parts:

• Third-quarter performance and continued spine-market softness;
• The anticipated effects of the U.S. spine distribution changes;
• International Limb Reconstruction order timing;
• Foreign-exchange headwinds.

The non-GAAP pro forma guidance excludes the discontinued M6 product lines.

What about 2027?

For the fourth quarter, Orthofix expects sequential growth from normal seasonality and inventory purchases under a European distributor arrangement. Most of the approximately $15 million sales benefit expected from that arrangement in 2026 should be recognized in the fourth quarter, Andrews said. Related inventory cash outflows are expected this year, while cash receipts are expected in 2027.

One timing effect deserves attention. Orthofix expects its European Medical Device Regulation strategy for spine to create an approximately $22 million sales headwind in 2027. Andrews described it as a temporary, regulatory-driven revenue timing effect rather than a change in underlying demand. Regulatory calendars, unlike demand, do not negotiate.

The company plans to provide formal 2027 guidance on its fourth-quarter call. Excluding the MDR effect, Andrews said management expects core revenue growth to be positive next year as it works through supplier issues and begins the year with a full quarter of VIRATA launch activity.

Orthofix Medical develops, manufactures and distributes spinal and orthopedic products, including spinal fixation and interbody systems, biologics and bone-grafting products, bone growth stimulation devices, and technologies for spinal motion preservation and deformity correction.

The verdict: a restructuring dressed as a guidance cut. Whether the distributor consolidation restores growth, the fourth quarter should say.